DRUG THERAPY FOR PROTEIN COMPOSITION CHANGES OF BLOOD IN HYPERTENSION AND IN CASES OF COMORBIDITY
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2021.2.12682Keywords:
hypertension, non-alcoholic steatohepatitis, type 2 diabetes mellitus, binding function of serum albumin, Antral®Abstract
Background. The binding function of serum albumin (BFSA) and its changes in various diseases in recent years are of interest to researchers. Hypertension (HT) in combination with comorbidities, including non-alcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (DM) can contribute to BFSA.
Objective. The aim of this study is to evaluate the relationship between quantitative changes in BFSA, protein fractions and indicators of endogenous intoxication (EI) in HT in combination with NASH and type 2 diabetes and to suggest drug therapy of the disorders revealed.
Methods. 123 patients with stage 2 HT and degree 2-3 arterial hypertension were examined; they were divided into three groups: group 1 included 28 patients without concomitant diseases, 2 – 48 patients with concomitant NASH, 3 – 47 patients with NASH and type 2 diabetes. Groups 3 and 4 were divided into two subgroups (A and B): patients of the subgroup A received basic HT therapy and additionally Antral® 200 mg 3 times a day for 60 days, B – only basic HT therapy. All patients underwent a standard clinical examination, as well as for BFSA, total protein, albumin, globulins and albumin-globulin ratio, medium mass molecules (MMM) at 280 and 254 nm and erythrocyte intoxication index (EII). The comparison group consisted of 25 healthy individuals.
Results. It was found out that Antral® in patients with HT in combination with NASH and with NASH and type 2 diabetes with a statistically significant decrease in BFSA, total protein and albumin, as well as with increased indicators of EI (MSM254, MSM280 and EII) caused significant improvement in BFSA, increase of total protein, serum albumin, reduce of MSM254, MSM280, EII and strengthening of all correlations.
Conclusions. Antral® therapy in patients with HT in combination with NASH as well as NASH and type 2 diabetes causes significant increase in BFSA, serum protein fractions and decreases EI.
References
Kligunenko EN, Zozulya OA. Human serum albumin (past and future). Meditsina neotlojnyih sostoyaniy. 2017;5(84):26-30. [In Russian].
DOI: 10.22141/2224-0586.5.84.2017.109356
Fanali G, Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol. Aspects Med. 2012;33(3):209-90.
DOI: 10.1016/j.mam.2011.12.002
Andreichyn SM, Skirak ZS. Effect of glutargine on serum albumin binding function and other indicators of liver function in acute toxic hydrazine hepatitis. Medychna ta klinichna khimiia. 2014;4:66-69. [In Ukrainian].
Cherkasova VV. The role of medium weight molecules in experimental L-arginine-induced pancreatitis and in dexamethasone correction. Aktualni problemy transportnoi medytsyny. 2017;2(48):125-130. [In Ukrainian].
Skirak ZS. Indicators of endogenous intoxication and lipoperoxidation in the dynamics of acute toxic carbon tetrachloride hepatitis. Infektsiini khvoroby. 2014;3:89-92. [In Ukrainian].
Drozdova IV, Babets AA, Stepanova LH, Omelnytska LV. Morbidity, prevalence and disability due to hypertension: approaches to analysis and prediction. Ukrainskyi kardiolohichnyi zhurnal. 2017;1:85-93. [In Ukrainian].
Vdovychenko VI, Kulchytskyi VV. Hypertension in combination with type 2 diabetes mellitus: conflicting views on management tactics. Ukrainskyi terapevtychnyi zhurnal. 2015;1:63-68. [In Ukrainian].
Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can. J. Cardiol. 2017;33(5): 557-576. DOI:10.1016/j.cjca.2018.02.022
Stepanov YuM, Filippova, AYu. Clinical features of the course of non-alcoholic steatohepatitis depending on concomitant diseases. Suchasna gastroenterologіya. 2006;29.3:4-7. [In Russian].
Skirak ZS. Violation of the binding function of serum albumin in toxic hepatitis [dissertation]. Ternopil: Ternop. nats. med. un-t; 2016.161 p. [In Ukrainian].
Kiriienko VT, Potii VV. The effectiveness of antral in patients with chronic hepatitis C. Bulletin of scientific research. Visnyk naukovykh doslidzhen. 2015;3:28-30. [In Ukrainian].
Koval SM., Snihurska IO, Penkova MY, Bozhko VV, Yushko KO. Arterial hypertension and diabetes mellitus: questions of optimizing the control of arterial pressure. Hypertension. 2018;2.58:9-18.
Barle H, Januszkiewicz A, Hallstrom L, et al. Albumin synthesis in humans increases immediately following the administration of endotoxin. Clin Sci (Lond). 2002;103(5):525-531.
Borysov SO, Kostiev FI, Borysov OV. Detoxifying effect of Antral on the course of obstructive nephropathy. Zdorovie muzhchiny. 2013;4:193-193. [In Ukrainian].
Zvyagintseva TD, CHernobay AI. The use of Antral in the treatment of non-alcoholic steatohepatitis: present and future. Chelovek i Lekarstvo – Kazahstan. 2016;17(78):84. [In Russian].
Babak OYA, Fadeenko GD, Kolesnikova EV. Experience in the use of the drug Antral in the complex therapy of non-alcoholic fatty liver disease. Consilium Medicum Ukraina. 2010;5(4):22. [In Russian].
Tkach SM. Efficacy and safety of hepatoprotectors from the point of view of evidence-based medicine. Zdorov’ya Ukrainy. 2009;6(1):7-10. [In Russian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Medicine and Medical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
